MicroPort® CRM and MicroPort® EP Participate in the 2023 Annual Meeting of the European Heart Rhythm Association

Barcelona, Spain, 18 May 2023 - Recently, the annual congress of the European Heart Rhythm Association (EHRA) was held in Barcelona, Spain. MicroPort® CRM and Shanghai MicroPort EP MedTech Co., Ltd. (hereinafter referred to as "MicroPort® EP") attended the congress together, showcasing their latest products and attracting hundreds of cardiovascular experts from Europe and around the world to offer them product experiences and demonstrations.

Established in 2003, the EHRA has a 20-year history, and its annual congress is a leading academic conference in the field of cardiac rhythm management in Europe. During the exhibition, MicroPort® EP showcased comprehensive EP solutions, including the ColumbusTM 3D EP Navigation system V3 (hereinafter referred to as "ColumbusTM V3 system") and its accompanying FireMagicTM TrueForceTM ablation catheter (hereinafter referred to as "TrueForceTM ablation catheter") and other full series products, attracting electrophysiology experts from Spain, Germany, the UK, Belgium, Italy, and many other countries for onsite consultation and experience. After fully experiencing the products, the experts highly praised the stability and fluency of the ColumbusTM V3 system modeling, as well as the sensitivity and accuracy of the real-time response of the new TrueForceTM Ablation catheter and expressed their positive expectations for many upcoming products.

During the congress, MicroPort® CRM also held a specialized seminar on implantable cardioverter defibrillators (ICD), and the attending experts discussed how to reduce inappropriate shock rates, as well as how ICD products can provide better experiences for patients during magnetic resonance imaging scans.

Through this participation, MicroPort® CRM and MicroPort® EP demonstrated their research and development strength and humanistic care, while received positive feedback from the attending experts. In the future, the companies will adhere to the development concept of continuous innovation, listen to the clinical needs and suggestions of front-line doctors, and provide more high-quality integrated medical solutions for global patients and doctors.

About MicroPort® CRM

MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through its long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally.

For more information, please refer to www.microport.com.

About MicroPort® EP

Founded in Shanghai in 2010, Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort EP”, stock code: 688351.SH), a joint-stock subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is a global medical devices company focusing on the development, manufacturing, and marketing of minimally invasive medical devices for the treatment of cardiac arrhythmia disease. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These products are used by hundreds of physicians at over 600 hospitals across China and beyond. At MicroPort® EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.everpace.com.